ライフサイエンスコーパス: ankle-brachial index

1 intima-media thickness, carotid plaque, and ankle-brachial index).

2 ernal carotid intima-media thickness, or the ankle brachial index.

3 ned from cardiovascular risk factors and the ankle brachial index.

4 n increase in common femoral artery flow and ankle brachial index.

5 resistance, common femoral artery flow, and ankle brachial index.

6 ipheral revascularization and lower baseline ankle-brachial index.

7 dized testing for the presence of PAD by the ankle-brachial index.

8 lesterol, HDL cholesterol, leg symptoms, and ankle-brachial index.

9 ences in carotid intima-medial thickness and ankle-brachial index.

10 mean postprocedural increase of 0.23 in the ankle-brachial index.

11 , lipid and inflammatory biomarkers, and low ankle-brachial index.

12 l carotid artery intima-media thickness, and ankle-brachial index.

13 ignificant change in resting or postexercise ankle/brachial indexes.

14 matic PAD (12 men, age 67 +/- 10 years, mean ankle brachial index 0.62 +/- 0.13) were studied.

15 le, 53% diabetic, 64% with tissue loss, mean ankle-brachial index 0.41, and mean toe pressure 26 mm H

16 68 +/- 10 years) with mild-to-moderate PAD (ankle-brachial index 0.69 +/- 0.14) had their most sympt

17 fe (-0.06; 95% CI: -0.17, 0.03; P = .20), or ankle-brachial index (0.03; 95% CI: -0.08, 0.14; P = .57

18 PAD was defined based on an ankle.brachial index .0.90.

19 domized (mean age, 72.3 years [+/-7.1]; mean ankle brachial index, 0.66 [+/-0.15]), 40 (91%) complete

20 Technicians measured ankle-brachial index 6 years apart in 2,298 participants

21 Of 125 limbs with noncompressible ankle brachial index, 72 (57.6%) anterior tibial and 80

22 PAD was defined as ankle brachial index (ABI) < or =0.90 or history of lowe

23 ticipants included 332 men and women with an ankle brachial index (ABI) <0.90 and 212 with ABI 0.90 t

24 ticipants included 392 men and women with an ankle brachial index (ABI) <0.90 and 249 with ABI 0.90 t

25 The ankle brachial index (ABI) and measures of upper and low

26 enome-wide association studies (GWAS) of the ankle brachial index (ABI) and PAD (defined as an ABI <

27 disease (PAD), specific leg symptoms and the ankle brachial index (ABI) are cross-sectionally related

28 ears) free of known cardiovascular (CVD) had ankle brachial index (ABI) assessment of their bilateral

29 erotic progression was assessed by computing ankle brachial index (ABI) at baseline (1,582 participan

30 s of subclinical atherosclerosis such as the ankle brachial index (ABI) could improve risk prediction

31 A low ankle brachial index (ABI) indicates atherosclerosis and

32 The ankle brachial index (ABI) is a noninvasive, reliable me

33 that defined peripheral artery disease as an ankle brachial index (ABI) lower than or equal to 0.90.

34 on of chronic kidney disease (CKD) with high ankle brachial index (ABI) measurement and to compare it

35 sought to determine the association of high ankle brachial index (ABI) measurements with left ventri

36 achial-ankle pulse wave velocity (baPWV) and ankle brachial index (ABI) were significantly higher but

37 associations of low (<0.90) and high (>1.40) ankle brachial index (ABI) with risk of all-cause and ca

38 months and changes in circulating PC levels, ankle brachial index (ABI), and walking impairment quest

39 mance predict mortality independently of the ankle brachial index (ABI).

40 oderate arsenic exposure and incident PAD by ankle brachial index (ABI).

41 purpose of this study is to determine if an ankle-brachial index (ABI) >or=1.40 is associated with r

42 -sectional association of PAD, defined as an ankle-brachial index (ABI) <0.9, and renal insufficiency

43 The authors studied associations between ankle-brachial index (ABI) and subclinical atheroscleros

44 Ankle-brachial index (ABI) and TCO2 measurements were ob

45 ssible arteries (PCA) to those with a normal ankle-brachial index (ABI) and those with peripheral art

46 Ankle-brachial index (ABI) and toe-brachial index can be

47 reviewed the evidence on the use of resting ankle-brachial index (ABI) as a screening test for PAD o

48 atherosclerotic progression, measured by the ankle-brachial index (ABI) at 3 consecutive time points

49 invasive test for diagnosis of LE-PAD is the ankle-brachial index (ABI) at rest and typically an ABI

50 s to determine whether use of an alternative ankle-brachial index (ABI) calculation method improves m

51 The ankle-brachial index (ABI) is widely used in the clinica

52 Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had underg

53 The ankle-brachial index (ABI) provides information on both

54 ed associations of borderline and low normal ankle-brachial index (ABI) values with functional declin

55 The ankle-brachial index (ABI) was 1.2 on both sides (normal

56 ine the association of both a low and a high ankle-brachial index (ABI) with incident cardiovascular

57 dentify genetic variants associated with the ankle-brachial index (ABI), a noninvasive measure of PAD

58 It can be noninvasively diagnosed with the ankle-brachial index (ABI), a ratio of Doppler-recorded

59 on between PAD, defined by low values of the ankle-brachial index (ABI), and future CVD risk has been

60 Ankle-brachial index (ABI), coronary artery calcificatio

61 esence of plaque, intima media thickness and ankle-brachial index (ABI), for N = 549.

62 the coronary artery calcium (CAC) score, the ankle-brachial index (ABI), high-sensitivity C-reactive

63 systolic blood pressure ratio, also known as ankle-brachial index (ABI), in RA patients.

64 , using different methods of calculating the ankle-brachial index (ABI).

65 C score predicted amputation better than the ankle-brachial index (ABI).

66 tibial, and brachial arteries to obtain the ankle-brachial index (ABI).

67 aluated by history and by measurement of the ankle-brachial index (ABI).

68 herosclerotic occlusive disease and abnormal ankle-brachial index (ABI).

69 l (PWV), aortic augmentation index (AIX) and ankle-brachial index (ABI).

70 severity were established by the use of the ankle-brachial index (ABI).

71 ary artery calcium score (CAC score, >0), or ankle-brachial index (ABI, <0.90).

72 1) young healthy subjects (YH) (n = 10; mean ankle-brachial index [ABI] 1.0 +/- 0.1, mean age 30 +/-

73 LVM, LVM index, relative wall thickness, and ankle-brachial index (all P <0.01).

74 Plasma B2M correlated with ankle brachial index and functional capacity.

75 years, the 403 patients showed a significant ankle brachial index and toe brachial index deterioratio

76 isk factors, an inverse relationship between ankle-brachial index and cardiovascular events was obser

77 We assessed ankle-brachial index and hip bone mineral density, follo

78 participants with PAD, independently of the ankle-brachial index and other confounders.

79 No difference in pain-free walking distance, ankle-brachial index and quality of life was found durin

80 and tertiary end points included changes in ankle-brachial index and quality-of-life assessments.

81 otid intimal medial thickness, stenosis, and ankle brachial index) and risk of dementia, CHD, and tot

82 adjusted for age, sex, race, comorbidities, ankle brachial index, and other confounders.

83 y angiography, positron emission tomography, ankle-brachial index, and B-mode ultrasound.

84 fasting blood glucose, periodontal disease, ankle-brachial index, and carotid intima-media thickness

85 VM, LVM index, relative wall thickness, CAC, ankle-brachial index, and cIMT were more abnormal across

86 ted for age, sex, race, comorbid conditions, ankle-brachial index, and other confounders.

87 ed for age, gender, race, comorbidities, the ankle-brachial index, and other potential confounders.

88 is, pain score, pain-free walking distance, ankle-brachial index, and transcutaneous oxygen measurem

89 condary outcomes quality of life, rest pain, ankle-brachial index, and transcutaneous oxygen pressure

90 were independent of CVD risk factors or the ankle-brachial index, and VEGF treatment of ECs in vitro

91 sure, reduced vascular compliance, decreased ankle-brachial indexes, and adventitial thickening.

92 The mean+/-SD ankle brachial index at baseline was 0.63+/-0.16.

93 artery disease (PAD) identified by screening ankle-brachial index benefit from preventive therapies t

94 CVD mortality, adjusting for age, sex, race, ankle-brachial index, body mass index, smoking, comorbid

95 ery calcium, carotid intima-media thickness, ankle-brachial index, brachial flow-mediated dilation, h

96 ical success was defined as improved resting ankle brachial index by > or =0.10, relief of resting pa

97 model without B-type natriuretic peptide and ankle-brachial index (C statistic, 0.79; 95% CI, 0.75-0.

98 and subclinical disease measures, including ankle-brachial index, carotid intimal-medial thickness,

99 Secondary measures, including DeltaPWT, ankle-brachial index, claudication onset time, and quali

100 Analyses were adjusted for age, sex, race, ankle brachial index, comorbidities, and other confounde

101 ace, body mass index, physical activity, the ankle brachial index, comorbidities, and other confounde

102 Adjusting for age, sex, ankle brachial index, comorbidities, and other potential

103 pported angioplasty for CLI and LLC improves ankle brachial indexes comparable to tibial bypass, heal

104 MRA index, % wall volume, and ankle-brachial index correlated with most functional mea

105 0%, 6%, 2.6 (95% CI, 1.4-4.8), and 39.2; for ankle-brachial index criteria, 0.6%, 9%, 5%, 2.3 (95% CI

106 hen compared with patients enrolled based on ankle-brachial index criteria.

107 compared with patients enrolled based on the ankle-brachial index criterion.

108 S) 1999 to 2004 who underwent measurement of ankle brachial index, CRP, and fasting glucose and insul

109 sidered major progression, which was a -0.30 ankle brachial index decrease for LV-PAD and a -0.27 toe

110 on urine cadmium, potential confounders, and ankle brachial index determinations in the follow-up exa

111 s postoperatively with physical examination, ankle brachial index, duplex, and a quality-of-life ques

112 icity, comorbid conditions, body mass index, ankle-brachial index, education, leg symptoms, cigarette

113 Ankle-brachial index evaluation was also performed.

114 ses and disease severity measures, including ankle-brachial index, forced expiratory volume, and exer

115 tors of poorer cognitive performance were an ankle brachial index greater than 1.30 (OR, 18.56 [95% C

116 indirect measures of arterial stiffness, an ankle brachial index greater than 1.30 and increased blo

117 cle characteristics, greater declines in the ankle brachial index, greater declines in lower extremit

118 89 patients) with critical limb ischemia and ankle brachial index >/=1.4 who underwent lower extremit

119 persisted after excluding participants with ankle brachial index >1.4 only as well as in subgroups d

120 brachial flow-mediated dilation >5% change, ankle-brachial index >0.9 and <1.3, high-sensitivity C-r

121 Moreover, patients with lower ankle-brachial index had (1) a more delayed reactive hyp

122 tivity C-reactive protein <2 mg/L and normal ankle-brachial index had DLRs >0.80.

123 or a measure of subclinical atherosclerosis (ankle brachial index) had little impact on these associa

124 Coronary artery calcium, ankle-brachial index, high-sensitivity CRP, and family h

125 Coronary artery calcium, ankle-brachial index, high-sensitivity CRP, and family h

126 ion, baseline atrial fibrillation, and lower ankle-brachial index identify peripheral artery disease

127 The ankle-brachial index improved significantly (0.33+/-0.05

128 Mean ankle-brachial indexes improved from 0.53 +/- 0.25 to 0.

129 score than carotid intima-media thickness or ankle-brachial index in subjects without and with CKD (H

130 The ankle-brachial index in the Viabahn group significantly

131 dysfunction, microalbuminuria, and a reduced ankle-brachial index) in 2680 Framingham Study participa

132 common carotid intimal-medial thickness, and ankle-brachial index) in 5,172 US adults without clinica

133 ility of the first-line diagnostic test, the ankle-brachial index, in clinics; incorrect perceptions

134 clusion of carotid intima-media thickness or ankle-brachial index, inclusion of the coronary artery c

135 Ankle brachial indexes increased for all groups (CLI = 0

136 Cell therapy significantly increased ankle brachial index, increased transcutaneous oxygen te

137 lantar flexion inversely correlated with the ankle-brachial index, indicating that patients with more

138 Using the single criterion of an ankle brachial index less than 0.9 to define PAD, the pr

139 D risk: high-sensitivity C-reactive protein, ankle-brachial index, leukocyte count, fasting blood glu

140 class variable derived from body mass index, ankle-brachial index, low-density lipoprotein cholestero

141 heral artery disease had to be defined as an ankle-brachial index lower than or equal to 0.90.

142 .90, and severe prevalent PAD was defined as ankle brachial index </= 0.70, with both definitions als

143 Prevalent PAD was defined as ankle brachial index </= 0.90, and severe prevalent PAD

144 The mean prevalence of PAD (defined as an ankle brachial index </=0.9) was 5.5% (SE, 0.47%).

145 eripheral arterial disease was defined as an ankle brachial index <0.9 in at least 1 leg.

146 Participants were free of PAD, defined as an ankle brachial index <0.9 or >1.4 at baseline, and had c

147 of 470 cases of incident PAD, defined as an ankle brachial index <0.9 or >1.4, were identified.

148 Participants were 384 men and women with an ankle brachial index <0.90 followed for a median of 47 m

149 e cumulative incidence of PAD, defined by an ankle brachial index <0.90 or a confirmed PAD event, wit

150 articipants were 370 men and women with PAD (ankle brachial index <0.90) and 231 without PAD.

151 pheral arterial disease (PAD) was defined by ankle brachial index <0.90, coronary artery calcificatio

152 PAD participants (n=465) had an ankle brachial index <0.90.

153 s-sectional analysis, 6,653 subjects with an ankle brachial index <1.40 were analyzed.

154 en urinary BPA levels (in tertiles) and PAD (ankle-brachial index < 0.9, n = 63) using logistic regre

155 kle-brachial index was used to diagnose PAD (ankle-brachial index </= 0.9).

156 Patients were enrolled based on an abnormal ankle-brachial index </=0.80 or a previous lower extremi

157 We defined PAD as an ankle-brachial index </=0.90.

158 Patients age 35 to 85 years with an ankle-brachial index </=0.95 and without clinically reco

159 ltivariable modeling, previous LER, baseline ankle-brachial index <0.50, surgical LER, and longer tar

160 baseline Rutherford category 4 to 6, and an ankle-brachial index <0.8.

161 Incident PAD was determined by an ankle-brachial index <0.9 assessed at 2 subsequent exami

162 Incident PAD was defined as a new onset of ankle-brachial index <0.9 assessed at regular examinatio

163 PAD was defined as a baseline ankle-brachial index <0.9.

164 percentile for age, sex, and ethnicity; and ankle-brachial index <0.9.

165 PAD, which is defined as an ankle-brachial index <0.90 at the baseline visit, was di

166 PAD was defined as an ankle-brachial index <0.90 in either leg.

167 When any history of CVD or an ankle-brachial index <0.90 were added to the model, SS r

168 R 1.8, 95% CI 1.1-3.2, P=0.03), and baseline ankle-brachial index <=0.60 (HR 1.3 per 0.10 decrease, 9

169 Enrollment criteria included an ankle-brachial index <=0.80 or previous lower extremity

170 in patients with claudication demonstrating ankle/brachial index <0.8.

171 raction <50%, and peripheral artery disease (ankle-brachial index, <0.90).

172 Ankle brachial index measurement was performed at the ba

173 nkle Brachial Index) participants undergoing ankle brachial index measurement.

174 Of these patients, 47.5% underwent ankle-brachial index measurement, 38.7% duplex ultrasoun

175 Along with coronary artery calcium scanning, ankle-brachial index measurement, and carotid artery ult

176 isk factors, B-type natriuretic peptide, and ankle-brachial index (model 6) yielded modest improvemen

177 if they had intermittent claudication and an ankle brachial index of <0.85, or if they had a prior pe

178 Plasma was collected from PAD patients (ankle brachial index of <0.90; n=45) and subjects with r

179 age of 74.4 (6.6) years, and had a mean (SD) ankle brachial index of 0.67 (0.18).

180 Non-PAD participants (n=292) had an ankle brachial index of 0.90 to 1.30.

181 n=3787) had a history of claudication and an ankle-brachial index of <0.85 or prior revascularization

182 ting vascular obstruction of 50% or greater, ankle-brachial index of less than 0.90, or physician-dia

183 ast 50%), or coronary artery disease with an ankle-brachial index of less than 0.90.

184 taine stage IIa, able to walk >200 m) and an ankle-brachial index of less than or equal to 0.90 or to

185 ted vasodilation (assessed as the FMD%), the ankle-brachial index, or autopsy.

186 cant differences in claudication onset time, ankle-brachial index, or quality-of-life measurements be

187 etABI study (German Epidemiological Trial on Ankle Brachial Index) participants undergoing ankle brac

188 d differences in pain-free walking distance, ankle-brachial index, quality of life, progression to cr

189 active protein, family history of ASCVD, and ankle-brachial index recommendations by the American Col

190 h critical limb ischemia and noncompressible ankle brachial index results, the prevalence of occlusiv

191 Improvements in ankle-brachial index, Rutherford class, and quality of l

192 ation, but noninvasive measures, such as the ankle-brachial index, show that asymptomatic PAD is seve

193 Change in ankle-brachial index showed a similar relation (p for qu

194 , sex, race, comorbidities, body mass index, ankle brachial index, smoking, and walking exercise freq

195 djusted for age, sex, race, body mass index, ankle-brachial index, smoking, physical activity, and co

196 ent for age, sex, race, body mass index, the ankle-brachial index, smoking, physical activity, releva

197 iological measures including blood pressure, ankle-brachial index, spirometry, exhaled nitric oxide,

198 no carotid plaque, no family history, normal ankle-brachial index, test result <25th percentile (caro

199 Approximately 20% of patients undergoing ankle brachial index testing for critical limb ischemia

200 assessment of limb perfusion, including the ankle-brachial index, toe-brachial index, and other perf

201 en groups in secondary end points, including ankle-brachial index, toe-brachial index, pain relief, w

202 patients) precisely estimated the changes in ankle brachial index, transcutaneous oxygen tension, res

203 sted with carotid intima-media thickness and ankle-brachial index (two other measures of subclinical

204 Ankle-brachial index, ultrasound, and X-ray radiography

205 Ankle-brachial index values >or=1.40 have been associate

206 The ankle-brachial index values for the participants with SC

207 event was not increased, even at the lowest ankle-brachial index values, and was the same as in a pa

208 Ankle brachial index was measured, and participants repo

209 , brachial flow-mediated dilation was 0.024, ankle-brachial index was 0.036, carotid intima-media thi

210 ears, 73% were male, and the median baseline ankle-brachial index was 0.78.

211 The ankle-brachial index was used to diagnose PAD (ankle-bra

212 Creatinine, age, and ankle-brachial index were among the top predictors of at

213 ripheral revascularization, smoking, and the ankle-brachial index were predictive of ALI.

214 intima-media thickness, carotid plaque, and ankle-brachial index) were evaluated.